盐酸普萘洛尔(Propranolol Hydrochloride) - 药物靶点：β-adrenoceptors_在研适应症：缺氧，血管瘤，偏头痛_专利_临床

概要

基本信息

简介盐酸普萘洛尔是一种小分子药物，作用于β-肾上腺素受体，是一种β-肾上腺素受体拮抗剂。它的主要适应症包括高血压、心绞痛、心房颤动、心房早搏复杂性、心动过缓和心动过速。普萘洛尔可以通过阻断β-肾上腺素受体来减少心率和收缩力，降低血压和心脏氧耗。这种药物还可以用于预防偏头痛和手部震颤，以及减轻焦虑和精神失常症状。普萘洛尔的原研组织为阿斯利康，于1966年8月18日获得首次批准。

药物类型

小分子化药

别名

1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol、1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol、beta-Propranolol

+ [38]

靶点

β-adrenoceptors

作用机制

β-adrenoceptors拮抗剂(β-肾上腺素能受体家族拮抗剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Pierre Fabre Médicament SAS

Maruho Co., Ltd.河北冀中制药有限责任公司

+ [7]

非在研机构

Wyeth Pharmaceuticals LLC

最高研发阶段批准上市

首次获批日期

日本 (1966-08-18),

心绞痛心房颤动房性早搏+ [4]

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)、孤儿药 (欧盟)、优先审评 (中国)、孤儿药 (韩国)

登录后查看时间轴

结构

分子式C16H22ClNO2

InChIKeyZMRUPTIKESYGQW-UHFFFAOYSA-N

CAS号318-98-9

关联

401

项与盐酸普萘洛尔相关的临床试验

NCT05797662 / Not yet recruiting临床2期IIT

A Phase II Study of Propranolol for the Treatment of Kaposi Sarcoma in Children and Adults

A clinical study of propranolol for the treatment of Kaposi Sarcoma in children and adults. This study will be an open-label single armed treatment trial that will test the effectiveness and the safety of treating Kaposi Sarcoma with propranolol.

开始日期2025-07-01

申办/合作机构

National Cancer Institute

NCT06066710 / Recruiting早期临床1期IIT

Trial of Propranolol in Older Adults with Primary Progressive Aphasia

The purpose of this study is to find out how the language of people with Primary Progressive Aphasia is affected by Propranolol. Propranolol is not FDA approved for the treatment of Primary Progressive Aphasia. Propranolol is FDA approved for the treatment of heart conditions such as blood pressure.
This research is being done because there are currently no drug treatment options for language impairments and anxiety often experienced by people with Primary Progressive Aphasia.

开始日期2025-03-01

申办/合作机构

University of Missouri

NCT06445166 / Not yet recruiting临床2期IIT

A Multicenter Phase II Study of Propranolol for the Treatment of Kaposi Sarcoma in Adults

Kaposi sarcoma (KS) lesions are initiated by endothelial cells infected with KS herpesvirus (KSHV), also known as human herpesvirus 8 (HHV-8). Lesion progression is driven by abnormal angiogenesis, chronic inflammation, and uncontrolled cell proliferation. KS remains one of the most commonly diagnosed cancers in many African countries where economic constraints prevent successful treatment in most patients. Treatment outcomes in developed countries are also often unsatisfactory in HIV positive patients despite good virological and immunological responses to antiretroviral therapy. Therefore, identification of new oral, safe treatment options for treatment of KS remains a research priority. Given the known anti-angiogenic properties and based on the treatment response with other benign vascular lesions such as infantile hemangioma, propranolol is a good candidate for the treatment of KS. The hypothesis of this study is that treating patients with Kaposi sarcoma with propranolol will result in an overall response rate (complete response rate plus partial response rate) of at least 45%, and that propranolol will be safe and well tolerated in this patient population.

开始日期2024-12-31

申办/合作机构

Washington University School of Medicine

100 项与盐酸普萘洛尔相关的临床结果

登录后查看更多信息

100 项与盐酸普萘洛尔相关的转化医学

登录后查看更多信息

100 项与盐酸普萘洛尔相关的专利（医药）

登录后查看更多信息

52,629

项与盐酸普萘洛尔相关的文献（医药）

2025-03-01·BEHAVIOURAL BRAIN RESEARCH

Exploring the contribution of the dopaminergic and noradrenergic systems in the antidepressant-like action of 1-(2-(4-(4-ethylphenyl)-1H-1,2,3-triazol-1-yl)phenyl)ethanone in mice

Article

作者: Goulart, Taís Barcelos ; Zuge, Narryman Pinto ; da Rocha, Marcia Juciele ; Presa, Marcelo Heinemann ; Bortolatto, Cristiani Folharini ; Brüning, César Augusto ; Ledebuhr, Kauane Nayara Bahr ; Alves, Diego

1-(2-(4-(4-ethylphenyl)-1H-1,2,3-triazol-1-yl)phenyl)ethanone (ETAP) is a novel hybrid compound containing 1,2,3-triazole and acetophenone. It exhibits antidepressant-like effects in male mice, linked to modulation of serotonergic receptors and monoamine oxidase A (MAO-A) inhibition. This study aimed to evaluate the involvement of the dopaminergic and noradrenergic systems, as well as MAO-B activity inhibition, in the antidepressant-like effect of ETAP in male mice, and to evaluate the antidepressant-like effect of ETAP in female mice. Male mice were treated with different dopaminergic and noradrenergic receptors antagonists 15 min before administering ETAP (1 mg/kg, intragastrically, i.g.). The tail suspension test (TST) was performed 30 minutes later. Different male mice were treated with ETAP (1 mg/kg, i.g.), and 30 minutes later, were euthanized to assess MAO-B activity in the prefrontal cortex and hippocampus. To evaluate the antidepressant-like of ETAP in female mice, ETAP (1 mg/kg, i.g.) was administered, followed by the TST and the forced swimming test (FST) 30 minutes later. The dopaminergic antagonists haloperidol (0.05 mg/kg, intraperitoneally, i.p.), SCH23390 (0.01 mg/kg, subcutaneously, s.c.), and sulpiride (50 mg/kg, i.p.), as well the noradrenergic antagonists prazosin (1 mg/kg, i.p.), yohimbine (1 mg/kg, i.p.), and propranolol (2 mg/kg, i.p.), prevented the antidepressant-like effect of ETAP in the TST. MAO-B activity was unaffected by ETAP in both the prefrontal cortex and hippocampus. ETAP (1 mg/kg, i.g.) induced a significant antidepressant-like effect in female mice in the TST and FST. These findings provide valuable insights into the antidepressant-like effect of ETAP, highlighting its potential for developing more effective depression treatments.

2025-03-01·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

Eco-friendly synchronous spectrofluorimetry coupled with chemometrics for simultaneous determination of ezetimibe and propranolol in pharmaceutical formulations and spiked plasma samples

Article

作者: Alqahtani, Taha ; Alshehri, Adil ; Almrasy, Ahmed A. ; Fatease, Adel Al ; Alqahtani, Ali ; Almrasy, Ahmed A

In this study, synchronous fluorescence spectroscopic methods coupled with chemometric techniques were developed and evaluated for the simultaneous quantification of ezetimibe and propranolol, two commonly prescribed cardiovascular drugs. Both drugs exhibit overlapping native fluorescence, posing a challenge for their selective determination. To address this, chemometric models including partial least squares (PLS) and genetic algorithm-based variable selection (GA) were constructed using a calibration dataset based on a 5² factorial design resulting in 25 synthetic mixtures. The developed method has been optimized to account for factors such as solvent composition, micellar systems, and excitation/emission wavelengths that affect the fluorescence signals. The PLS and GA-PLS models were validated using an independent test set of 13 samples based on central composite design revealing the GA-PLS model provided improved quantitative performance with relative root mean square error of prediction (RRMSEP) values of 1.3939 and 1.0005 % for ezetimibe and propranolol, respectively, compared to 2.2502 and 2.3526 % for the PLS models. Hence, the GA-PLS models were successfully applied for the determination of ezetimibe and propranolol in pharmaceutical formulations and spiked plasma samples. Furthermore, the greenness and blueness of the proposed methods were compared against reported HPLC procedures using the AGREE and BAGI tools, revealing a greener analytical footprint for the developed method and higher analytical practicability posing as an environmental-friendly alternative to the standard HPLC technique.

2025-03-01·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

Carbon dot-based molecularly imprinted polymer fluorescent sensor for the detection of propranolol in plasma

Article

作者: Fu, Dongju ; Li, Ruizhen ; Qin, Lei ; Liu, Jialin ; Liu, Xuguang ; Liu, Weifeng ; Wang, Moeiling

Propranolol, a medication used to treat cardiovascular diseases, can be harmful when overdosed and hazardous to ecosystems if released into the environment. Here, a new molecularly imprinted fluorescent sensor was developed from carbon dots through a sol-gel method. Carbon dots served as both the fluorescent signal and the carrier, with propranolol as the template molecule and 3-aminopropyltriethoxysilane as the functional monomer to be grafted on carbon dots' surface. A novel detection method was established for the efficient, rapid, and cost-effective detection of propranolol in human plasma through quantitative analysis by using a fluorescence spectrophotometer and an ultraviolet spectrophotometer. Under the optimal conditions, the detection range of 0.5-4 mg L^-1, the detection limit of 0.092 mg L^-1, the imprinting factor of 2.42, and the detection response time of 2 min were achieved. The prepared carbon dot-based molecularly imprinted fluorescent sensor was proved to have a wide accurate linear range, low detection limit, and very short response time, and can detect lower analyte concentrations with higher detection accuracy.

134

项与盐酸普萘洛尔相关的新闻（医药）

2024-12-28

·Insight数据库

21 款新药在国内申报上市，5 款为抗肿瘤新药

根据 Insight 数据库，共计有 21 款新药在 12 月向 CDE 递交了上市申请（截至 12 月 27 日，含新适应症），包括 13 款进口药，8 款国产药。药物类型上，8 款为生物药，13 款为化药。本文将对其中的 5 款抗肿瘤新药信息做介绍，仅供参阅。 GSK：玛贝兰妥单抗全球首个 BCMA ADC 12 月 7 日，葛兰素史克的注射用玛贝兰妥单抗上市申请获得受理。该申请已被纳入优先审评，适应症为玛贝兰妥单抗与硼替佐米+地塞米松联合治疗既往接受过至少一种治疗的多发性骨髓瘤（MM）成年患者。截图来源：CDE 官网玛贝兰妥单抗是全球首款申报上市的 BCMA ADC。在 Ⅲ 期临床试验 DREAMM-7 中，研究人员评估了玛贝兰妥单抗+硼替佐米+地塞米松治疗复发/难治性多发性骨髓瘤患者的疗效和安全性，对照组为达雷妥尤单抗 +硼替佐米+地塞米松。研究主要终点是 PFS。 2024 年 ASCO 年会上公布的数据显示，在意向治疗人群 (ITT) 中：中位 PFS 方面，玛贝兰妥单抗组为 36.6 个月，显著高于达雷妥尤单抗组的 13.4 个月; 与标准治疗达雷妥尤单抗组相比，玛贝兰妥单抗组将患者病情进展或死亡风险降低了 59%； ORR 方面，玛贝兰妥单抗组为 82.7%，高于达雷妥尤单抗组的 71.3%；此外，玛贝兰妥单抗组治疗在总体生存率方面呈现出强劲、具有临床意义的趋势，死亡风险降低了 43%。石药集团：SYHX2011 创新纳米制剂 12 月 10 日，石药集团 2.2 类新药 SYHX2011 申报上市，用于既往经联合化疗失败的转移性乳腺癌或辅助化疗后 6 个月内复发的乳腺癌。截图来源：CED 官网 SYHX2011 是一种创新型纳米制剂。Ⅲ 期临床试验结果显示，与注射用紫杉醇（白蛋白结合型）相比，该药在晚期乳腺癌患者中具有更显著的疗效。 IRC 及研究者评估的 ORR 组间比值分别为 1.38 和 1.33，均达到优效标准；疾病进展或死亡风险降低 27%，死亡风险降低 33%。在安全性方面，SYHX2011 的皮疹发生风险降低 62%；在临床应用方面，其配液时长明显缩短，解决了注射用紫杉醇（白蛋白结合型）使用前配液操作复杂、复溶时间长的问题。梅尔森/华邦制药：噻吗洛尔凝胶婴幼儿血管瘤外用制剂 12 月 12 日，梅尔森医药和华邦制药联合递交了马来酸噻吗洛尔凝胶的上市申请，该申请已被纳入优先审评，用于治疗增殖期浅表性婴儿血管瘤。截图来源：CED 官网婴幼儿血管瘤是来源于血管内皮细胞的先天性肿瘤，是儿童时期常见的一种良性肿瘤。口服普萘洛尔（非选择性 β-肾上腺素受体阻滞剂）一直是血管瘤的一线治疗选择，但是接受治疗的患儿会有全身不良反应，包括心率下降、低血压、胃肠道反应、低血糖等等。噻吗洛尔也是一种非选择性 β-肾上腺素受体阻滞剂，此前在临床上主要用于治疗高眼压、开角型青光眼。后来研究发现，噻吗洛尔也有治疗血管瘤的作用，而且对患儿的血压和心率影响更小，逐渐被开发用于治疗血管瘤。噻吗洛尔可能通过促进血管收缩、抑制血管内皮细胞异常增殖、诱导细胞凋亡等作用机制，达到治疗婴幼儿血管瘤的效果。 Insight 数据库显示，目前全球仅有 1 款婴幼儿血管瘤药物获批，即口服普萘洛尔。梅尔森医药和华邦制药报上市的马来酸噻吗洛尔凝胶是一种外用制剂。此外，今年 11 月，奥全生物的马来酸噻吗洛尔凝胶也已在国内报上市，同样被纳入了优先审评。由此可见，全球首款婴幼儿血管瘤的外用药物大概率是要花落梅尔森医药/华邦制药、奥全生物两家公司了。鞍石生物：伯瑞替尼递交 MET 扩增 NSCLC 适应症 12 月 26 日，鞍石生物子公司浦润奥生物递交了 MET 抑制剂「伯瑞替尼肠溶胶囊」的第三项新适应症上市申请，用于治疗具有 MET 扩增的局部晚期或转移性非小细胞肺癌（NSCLC）患者。该申请此前已被纳入优先审评。截图来源：CDE 官网伯瑞替尼是一种高选择性的 c-MET 抑制剂，此前已在国内获批两项适应症，分别用于治疗：1）具有 MET 外显子 14 跳变的局部晚期或转移性 NSCLC 患者；2）既往治疗失败的具有 PTPRZ1-MET 融合基因的 IDH 突变型星形细胞瘤（WHO 4 级）或有低级别病史的胶质母细胞瘤成人患者，是目前唯一在国内获批胶质母细胞瘤适应症的 MET 抑制剂。本次新适应症的递交是基于一项多中心、多队列、开放标签 II 期 KUNPENG 研究。其中：经治队列主要纳入未接受过 MET 抑制剂治疗、标准治疗（含铂化疗方案）失败或临床上不适合进行标准治疗的 MET 扩增患者；初治队列主要纳入未接受过 MET 抑制剂治疗、拒绝化疗的 MET 扩增患者。鞍石生物尚未对外披露该研究的具体数据。诺华：卡马替尼递交第二项 NDA 12 月 21 日，诺华卡马替尼递交了新适应症上市申请。卡马替尼是一种 c-MET 抑制剂，今年 6 月首次在国内获批，用于未经系统治疗的携带 MET 外显子 14 跳跃突变的局部晚期或转移性 NSCLC 成人患者。截图来源：CDE 官网在国内，诺华正在开展一项多中心、双队列 II 期研究，以评估卡马替尼在初治或既往一线或二线系统治疗失败的 EGFR 野生型、ALK 重排阴性、MET 外显子 14 跳跃突变的晚期 NSCLC 的效果。该研究的主要目的是支持卡马替尼在国内的上市申请。目前一线适应症已经获批，本次申报的有可能是后线适应症。除了上述抗肿瘤新药，本月还有多款其它新药在国内递交了首个 NDA（见下表），限于篇幅，本文不再一一介绍。封面来源：站酷海洛 Plus 免责声明：本文仅作信息分享，不代表 Insight 立场和观点，也不作治疗方案推荐和介绍。如有需求，请咨询和联系正规医疗机构。编辑：馨药 PR 稿对接：微信 insightxb 投稿：微信 insightxb；邮箱 insight@dxy.cn 多样化功能、可溯源数据…… Insight 数据库网页版等你体验点击阅读原文，立刻解锁！

优先审批临床3期申请上市ASCO会议抗体药物偶联物

2024-12-27

·Business Wire

Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech

CHICAGO--( BUSINESS WIRE )--Exicure, Inc. (Nasdaq: XCUR, “Exicure”, “the Company”), has announced the signing of a Memorandum of Understanding (MOU) with GPCR Therapeutics, Inc. (“GPCR Therapeutics”) on December 24, 2024, aimed at the acquisition of GPCR USA, a subsidiary of GPCR Therapeutics, and the technology transfer and collaborative research on GPCR Therapeutics’ ongoing drug development pipelines. Through this acquisition, Exicure plans to secure key technical personnel by purchasing all shares of GPCR USA held by GPCR Therapeutics. Following this, Exicure intends to receive technology transfer for GPCR Therapeutics’ CXCR4 inhibitor, which is currently in Phase 2 clinical trials with the FDA, along with its related patents and intellectual property (IP). By acquiring excellent research personnel and clinical pipelines, Exicure aims to advance as a clinical-stage biotech company. GPCR Therapeutics plans to successfully finalize ongoing clinical trials involving stem cell mobilizers (SCM) targeting multiple myeloma patients and prepare for clinical studies related to acute myeloid leukemia (AML). The market size for the ongoing Phase 2 trials is estimated to be around $1 billion to $2 billion annually. Moreover, Exicure plans to engage in collaborative research and development in various forms for GPCR Therapeutics’ ongoing research in immuno-oncology, fibrosis treatments, and obesity therapies. GPCR Therapeutics, the partner with Exicure in this MOU, is a South Korean drug development company specializing in GPCR (G Protein-Coupled Receptor, “GPCR”), which represents over one-third of all drug targets. GPCR Therapeutics has secured target patents around prominent GPCRs such as CXCR4 and possesses multiple pipelines addressing blood cancers and solid tumors, genetic disorders, idiopathic pulmonary fibrosis, and obesity, including ongoing Phase 2 trials in the U.S. for multiple myeloma. Dr. Pina Cardarelli, who previously served as Vice President at Bristol-Myers Squibb, where she led the development of the first-ever immuno-oncology drugs, Yervoy (ipilimumab) and Opdivo (nivolumab), has served as the Chief Scientific Officer (CSO) of GPCR Therapeutics since 2019. In 2021, GPCR Therapeutics established a subsidiary in the U.S. to align its R&D with global pharmaceutical standards and demands. During the American Society of Hematology (ASH) conference held from December 7-10, 2024, GPCR Therapeutics presented three exhibits detailing: (1) interim results from ongoing Phase 2 trials, (2) data on enhancing treatment efficacy for acute myeloid leukemia (AML), and (3) preclinical data on boosting T cell responses to offer various therapies, including in vivo CAR-T. Additionally, on December 24, 2024, Exicure completed the $8.7 million capital investment. Combined with the $2 million capital investment executed on December 9, 2024, the $1.3 million raised in November, and an expected additional $4 million, the Company plans to secure a total of $14 million in capital investments. The funds will primarily be used for the acquisition of GPCR USA, clinical trial costs, and its ongoing operations. About GPCR Therapeutics, Inc. GPCR Therapeutics, Inc., headquartered in Seoul, South Korea, is a clinical-stage international biopharmaceutical company with an innovative approach to developing therapeutics built on its proprietary GPCR data. The company’s lead small molecule asset, GPC-100/Burixafor, targets CXCR4, one of the most prevalent chemokine GPCRs overexpressed in various cancers. GPCR Therapeutics is currently conducting a Phase 2 clinical trial in the U.S. to assess the efficacy of the combination of GPC-100 and propranolol in patients with multiple myeloma. The company is also actively collaborating with domestic and international biotechnology firms. By targeting the unique pharmacology of GPCR pairs, GPCR Therapeutics aims to develop life-changing treatments for cancer and other diseases. Notably, the interaction between CXCR4 and the beta-2 adrenergic receptor (B2AR) presents an alternative signaling pathway that is synergistically dependent on the activation of both CXCR4 and B2AR. About Exicure, Inc. Exicure, Inc. has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Following its recent restructuring and suspension of clinical and development activities, the Company is exploring strategic alternatives to maximize stockholder value, both with respect to its historical biotechnology assets and more broadly. For further information, see www.exicuretx.com . Forward-Looking Statements This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. There can be no assurance regarding our ability to comply with the Panel’s decision and the applicable listing criteria by the deadline or thereafter. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual outcomes to differ materially from the outcomes expressed or implied by this report. Such risks include, among others, the possibility we will not be able to cure existing listing deficiencies, the possibility of additional deficiencies, the risk that the Company may not adequately comply with the terms of the Panel’s decision, and the risk that Nasdaq will ultimately delist the Company’s common stock. All such factors are difficult to predict and may be beyond the Company’s control. The Company undertakes no obligation and does not intend to update or revise any forward-looking statements contained herein, except as required by law or regulation. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this report.

临床2期ASH会议并购

2024-12-26

·丁香园

年轻男性突发四肢瘫痪，居然是因为吃太多了……

5 丁香园神经科讨论群（498） @所有人早查房：20 岁男性，四肢瘫痪急性发作 7 小时，逐渐恶化。查体：上肢对称肌力 4/5，双侧髋关节和膝关节屈伸对称肌力 2/5，踝关节背屈和跖屈 4/5。实验室检查：血钾偏低。 MRI 正常。患者突发瘫痪可能原因是什么？需补充哪些检查？如何治疗？青年男性，询问家族史，晚善甲功检查，考虑低钾性周期性麻痹，补钾补够了，上午轮椅进医院的，下午自己走出去，效果立马见影我猜吃了很多碳水化合物，导致血钾低，低钾性周期瘫痪，完善甲功检查，主要是补钾治疗男性，青年，急性病程，伴低钾，首先完善甲功。询问有无暴饮暴食，夜间吃完烧烤啤酒低钾就来了 9:30 低钾周麻可能性大。检查肌酶，肌电图等排查其他病因。完善尿电解质，甲功ANA抗体谱等排查低钾原因。治疗予补钾，病因明确后治疗原发病。 1.低钾型周期性麻痹。2.急性格林巴利综合征。查肌酶、甲功、肌电图、腰穿。 @所有人公布答案：仔细询问病史发现，患者近期曾参加葬礼，并且有大量进食的情况，自述心理压力很大，过去 4 个月明显消瘦。根据近期应激事件、食用富含碳水化合物的食物后急性发作四肢瘫痪病史，结合低血钾，考虑低钾型周期性麻痹（PP）。大多数 PP 为遗传性，获得性低钾血性 PP 一般与甲状腺功能亢进有关，考虑补充甲状腺激素检测：促甲状腺激素 <0.01 mIU/L，游离 T3 13.1 pg/mL，游离 T4 3.8 ng/dL，促甲状腺免疫球蛋白 1.44 IU/L。最终确诊：甲状腺毒性周期性麻痹（TPP）。多数 TPP 患者会表现为肌张力下降+反射减退，本例患者比较特殊，表现为反射亢进。后续治疗：补钾，普萘洛尔、甲巯咪唑治疗，患者运动强度恢复，肌张力增加。

临床结果疫苗

100 项与盐酸普萘洛尔相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00483	盐酸普萘洛尔	C07AA05	DB00571

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
缺氧	日本	Taiyo Pharma Co., Ltd.	2014-11-18
血管瘤	美国	Pierre Fabre SA	2014-03-14
原发性高血压	日本	Taiyo Pharma Co., Ltd.	1978-08-01
肥大型心肌病	美国	Wyeth Pharmaceuticals LLC	1967-11-13
冠心病	美国	Wyeth Pharmaceuticals LLC	1967-11-13
特发性震颤	美国	Wyeth Pharmaceuticals LLC	1967-11-13
高血压	美国	Wyeth Pharmaceuticals LLC	1967-11-13
偏头痛	美国	Wyeth Pharmaceuticals LLC	1967-11-13
心肌梗塞	美国	Wyeth Pharmaceuticals LLC	1967-11-13
心绞痛	日本	Taiyo Pharma Co., Ltd.	1966-08-18
心房颤动	日本	Taiyo Pharma Co., Ltd.	1966-08-18
房性早搏	日本	Taiyo Pharma Co., Ltd.	1966-08-18
心动过缓	日本	Taiyo Pharma Co., Ltd.	1966-08-18
嗜铬细胞瘤	日本	Taiyo Pharma Co., Ltd.	1966-08-18
心动过速	日本	Taiyo Pharma Co., Ltd.	1966-08-18
窦性心动过速	日本	Taiyo Pharma Co., Ltd.	1966-08-18

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
毛细血管瘤	临床3期	美国	Pierre Fabre SA	2010-01-01
毛细血管瘤	临床3期	澳大利亚	Pierre Fabre SA	2010-01-01
毛细血管瘤	临床3期	加拿大	Pierre Fabre SA	2010-01-01
毛细血管瘤	临床3期	捷克	Pierre Fabre SA	2010-01-01
毛细血管瘤	临床3期	法国	Pierre Fabre SA	2010-01-01
毛细血管瘤	临床3期	德国	Pierre Fabre SA	2010-01-01
毛细血管瘤	临床3期	匈牙利	Pierre Fabre SA	2010-01-01
毛细血管瘤	临床3期	意大利	Pierre Fabre SA	2010-01-01
毛细血管瘤	临床3期	立陶宛	Pierre Fabre SA	2010-01-01
毛细血管瘤	临床3期	墨西哥	Pierre Fabre SA	2010-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05561751 (ASH2024) 人工标引	临床2期	多发性骨髓瘤 CD34+	20	Propranolol+G-CSF+ Burixafor	壓齋網鬱顧鏇簾鑰襯糧(鏇壓餘蓋觸鏇鏇憲鑰壓) = 鏇膚鏇觸憲選壓鑰齋觸構獵憲淵艱積選淵選遞 (襯窪鏇簾鹹齋顧蓋選鑰 )	积极	2024-12-09
NCT03049306 (ProSAT, CTgov)	临床2期	阻塞性睡眠呼吸暂停综合征	24	Placebo Oral Tablet+Propranolol Oral Tablet (Placebo Oral Tablet)	簾膚顧顧遞鑰蓋醖觸醖(衊鬱艱顧遞鹽淵膚壓繭) = 願觸繭構膚夢窪糧憲願餘積齋夢廠簾糧簾淵鏇 (夢糧夢選顧顧築繭選獵, 窪窪願構繭艱齋衊廠網 ~ 衊淵衊餘製鏇膚糧鑰簾) 更多	-	2024-09-05
				Placebo Oral Tablet+Propranolol Oral Tablet (Propranolol Oral Tablet)	簾膚顧顧遞鑰蓋醖觸醖(衊鬱艱顧遞鹽淵膚壓繭) = 觸積簾鬱鬱齋齋選艱鏇餘積齋夢廠簾糧簾淵鏇 (夢糧夢選顧顧築繭選獵, 簾製窪鹽繭齋壓醖選糧 ~ 廠窪遞鏇齋鑰窪顧壓獵) 更多
ESC2024	N/A	室性早搏	-	Propranolol	衊窪構繭製築構鏇觸製(夢築觸艱築網壓範鏇獵) = 餘鏇遞膚築簾衊網夢窪網鏇鹹襯壓簾鑰遞鬱顧 (憲蓋蓋顧獵鹹選廠鏇淵, 7.7)	-	2024-04-09
				Propranolol (Catheter Ablation)	衊窪構繭製築構鏇觸製(夢築觸艱築網壓範鏇獵) = 鑰襯製繭艱獵獵簾獵網網鏇鹹襯壓簾鑰遞鬱顧 (憲蓋蓋顧獵鹹選廠鏇淵, 7.7)
NCT04757584 (CTgov)	临床4期	射血分数保留型心力衰竭 \| 舒张期心力衰竭	9	Beta blockers (Beta Blocker ABAB Sequence)	糧齋襯範願廠憲膚鹹願(窪觸網積選襯夢衊窪願) = 鹽憲願獵鹹壓夢蓋衊觸築鏇窪遞膚壓鑰窪獵壓 (窪衊淵遞艱顧衊願顧顧, 淵鑰鹹齋憲夢襯齋鹽願 ~ 顧襯遞夢製選鏇簾願憲) 更多	-	2024-04-09
				Beta blockers (Beta Blocker BABA Sequence)	糧齋襯範願廠憲膚鹹願(窪觸網積選襯夢衊窪願) = 餘獵鏇製製獵製觸顧製築鏇窪遞膚壓鑰窪獵壓 (窪衊淵遞艱顧衊願顧顧, 衊蓋選鬱繭構簾選鑰鏇 ~ 範衊願鬱獵廠衊積憲淵) 更多
NCT02428205 (CTgov)	N/A	自闭症 \| 心房中隔缺损	10	Propranolol (Propranolol Arm)	鬱廠糧鏇夢憲糧壓衊蓋(襯製觸糧願餘觸構選憲) = 觸醖積製選夢蓋淵窪範製襯選鑰憲簾選繭選選 (選醖膚鏇範築憲壓積壓, 鏇網夢顧蓋鹹願築積顧 ~ 顧積選鹽夢範醖鏇壓觸) 更多	-	2024-03-04
				Placebo (Placebo Arm)	鬱廠糧鏇夢憲糧壓衊蓋(襯製觸糧願餘觸構選憲) = 簾築遞廠獵遞網鹽鹽觸製襯選鑰憲簾選繭選選 (選醖膚鏇範築憲壓積壓, 鏇醖齋膚遞蓋顧窪觸遞 ~ 簾憲顧鏇構壓餘淵窪蓋) 更多
NCT02740166 (Pubmed \| Am J Gastroenterol) 人工标引	临床4期	食道静脉出血 cirrhosis	212	EVL plus propranolol till EEV	繭構鑰膚選憲窪繭網襯(齋憲獵鑰鬱製遞鹹構餘) = 齋簾醖築積窪積衊憲襯窪醖製廠淵齋製製齋餘 (衊選願餘艱淵壓簾淵窪 ) 更多	积极	2024-02-01
				EVL plus continupropranolololol	繭構鑰膚選憲窪繭網襯(齋憲獵鑰鬱製遞鹹構餘) = 鑰蓋選選簾艱窪鏇顧夢窪醖製廠淵齋製製齋餘 (衊選願餘艱淵壓簾淵窪 ) 更多
EADV2023	N/A	毛细血管瘤	50	Oral propranolol	積蓋築鏇顧壓壓醖醖餘(衊簾構簾鑰鏇醖鹹夢壓) = were seen only in very few cases 醖膚窪顧顧鏇網鹹顧製 (積簾築鏇窪窪範遞製製 )	积极	2023-10-11
NCT04299438 (PROPEL, CTgov)	临床3期	过期妊娠 \| 产程	164	Propranolol Hydrochloride (Propranolol)	網壓願醖廠膚窪膚選膚(鏇積鑰構鬱膚窪衊顧餘) = 醖齋積構願廠鏇鏇衊膚廠醖繭廠鬱選鹽醖構醖 (獵淵蓋淵窪網願製鏇構, 鏇蓋製齋蓋糧選觸膚遞 ~ 糧鏇鹽簾繭膚鹹遞夢願) 更多	-	2023-08-23
				Saline (Placebo)	網壓願醖廠膚窪膚選膚(鏇積鑰構鬱膚窪衊顧餘) = 衊憲鏇齋積齋餘積選範廠醖繭廠鬱選鹽醖構醖 (獵淵蓋淵窪網願製鏇構, 餘鹹鏇糧繭構繭廠窪鑰 ~ 餘觸襯醖鬱襯構餘製廠) 更多
NCT01322048 (Pubmed)	临床2期	创伤性脑损伤	47	Propranolol and Clonidine	蓋簾糧鏇範鑰餘願鹽壓(廠範簾獵鏇夢醖艱構積) = 選齋構積製淵衊蓋鬱鑰範衊衊鏇築膚襯廠艱廠 (顧壓鹽鹹淵廠簾範艱構, ( ~ 5.4, 5.8)) 更多	-	2023-06-09
NCT04299438 (Pubmed \| Obstet Gynecol)	临床3期	-	349	Propranolol	鏇壓淵鬱齋鏇艱窪製廠(簾觸鏇襯網艱積窪鏇餘) = 範鹽壓衊鹹遞範壓窪製鹹糧築壓衊餘選醖鏇艱 (製醖築築齋鹹壓選糧範 )	-	2023-06-08
				Placebo	鏇壓淵鬱齋鏇艱窪製廠(簾觸鏇襯網艱積窪鏇餘) = 簾餘淵鹹鹽積夢獵鑰膚鹹糧築壓衊餘選醖鏇艱 (製醖築築齋鹹壓選糧範 )